Few medicines have generated as much online chatter in such a short space of time as Foundayo. Since the MHRA authorised orforglipron on 10 August 2026, making the UK the first country in Europe to approve this GLP-1 weight loss tablet, social media, forums and word of mouth have filled in the gaps left by official information, and not always accurately. Ask five people what Foundayo actually does and you are likely to get five different, and often exaggerated, answers.
At Everest Pharmacy, we would rather patients walk into a future consultation with realistic expectations than with claims they have picked up from an Instagram comment or a friend of a friend. Foundayo genuinely is an exciting development, but exciting does not mean magic, and separating the two matters, particularly before a medicine has even launched for prescribing. This article works through the most common Foundayo myths currently circulating and sets out what is actually known, based on its UK authorisation, so far.
If you would like accurate, personalised information once Foundayo becomes available, contact our team or register your interest below.
Why Myths Spread So Quickly Around New Medicines
Whenever a genuinely significant medicine reaches the news, a predictable pattern follows. Early headlines focus on the most striking details, social media strips away nuance in favour of shareable claims, and by the time the information reaches most people, it has drifted a considerable distance from what was actually approved and why.
Foundayo is a useful case study in this pattern. Its UK authorisation is a real and notable milestone, but the way it has been discussed online has already produced a set of assumptions that go well beyond what has actually been confirmed. Before Foundayo becomes available for prescribing, it is worth working through the most common of these directly.
Myth: Foundayo Is Available To Buy Right Now
This is the most common misconception, and understandably so, given how much coverage the MHRA authorisation received. Authorisation and availability are two different things. Authorisation means the medicine has met the UK’s regulatory standards and can legally be prescribed, but providers still need to finalise supply, pricing and clinical pathways before patients can actually start treatment.
The fact: Foundayo is not yet available to prescribe anywhere in the UK, including at Everest Pharmacy. We are working towards launching it as soon as responsibly possible, and any website or seller claiming to supply it right now should be treated with real caution, as such products cannot be verified as genuine.
Myth: Foundayo Works Completely Differently To Everything Else
Because Foundayo has been described as a breakthrough, it is easy to assume it works through some entirely new mechanism unrelated to existing weight loss medicines. It doesn’t.
The fact: Foundayo is a GLP-1 receptor agonist, the same broad medicine class as semaglutide (used in Wegovy) and tirzepatide (used in Mounjaro). It reduces appetite and slows digestion by acting on the same hormonal pathway. What is genuinely different about Foundayo is its chemical structure, a small molecule rather than a peptide, which is why it can be taken without the food and water restrictions that apply to the Wegovy pill. The mechanism behind the appetite effect itself is not new.
Myth: Foundayo Will Produce Better Weight Loss Results Than Injections
This is one of the more persistent claims doing the rounds, often framed as “the tablet that beats the injection.” It is not accurate.
The fact: Based on the evidence supporting its approval, Foundayo’s average weight loss results sit below those typically reported for injectable treatments such as Mounjaro, and slightly below the Wegovy pill in some comparisons. Foundayo’s main advantage is convenience and accessibility, particularly for patients who have avoided GLP-1 treatment because of the injection, not superior effectiveness. Patients prioritising the highest possible weight loss may still be better suited to an injectable option.
Myth: There Are No Restrictions At All With Foundayo
Because Foundayo does not require the strict empty-stomach rule used with the Wegovy pill, some coverage has implied it comes with no rules whatsoever. This oversimplifies things considerably.
The fact: Foundayo still needs to be taken correctly, as a whole tablet, generally once daily, and it still comes with important safety considerations, including interactions with certain other medicines, precautions around pregnancy and contraception, and a gradual dose increase over several months. Removing the food and water timing rule is a genuine convenience, but it does not mean the medicine can be taken casually or without medical guidance.
Myth: Foundayo Has No Side Effects Because It’s A Tablet
There is a common assumption that because Foundayo is easier to take than an injection, it must also be gentler on the body. This is not the case.
The fact: Foundayo’s side effect profile is broadly similar to other GLP-1 medicines, since it works through the same underlying pathway. Commonly reported effects include nausea, constipation, diarrhoea and indigestion, particularly during the early stages of treatment or when the dose is increased. Rare but serious risks, including pancreatitis, are also relevant considerations. Format does not determine side effect severity, mechanism does.
Myth: Foundayo Will Be Available On The NHS Straight Away
Some assume that because a medicine has been authorised, NHS access will follow automatically and quickly.
The fact: MHRA authorisation and NHS availability are separate processes. NHS access to new medicines typically depends on a health technology assessment from a body such as NICE, which can take considerable time after authorisation. Everest Pharmacy intends to offer Foundayo through private prescription once it launches, regardless of the timeline for any future NHS decision.
Myth: Anyone Can Take Foundayo Once It’s Available
The framing around Foundayo as a convenient, needle-free option has led some to assume it will be an easy, low-barrier medicine to access.
The fact: Foundayo will remain a prescription-only medicine, requiring a full clinical assessment before it can be prescribed. It is unlikely to be suitable for patients with certain thyroid conditions, a history of pancreatitis, significant kidney or liver impairment, or those who are pregnant, breastfeeding or planning a pregnancy. Eligibility will also likely depend on BMI and overall health, assessed individually by a prescriber, in the same way as existing GLP-1 treatments.
Setting Realistic Expectations: What Foundayo Genuinely Offers
Stripping away the hype does not mean Foundayo isn’t a meaningful development, it clearly is. What it genuinely offers is:
- A needle-free GLP-1 option for patients who have previously avoided treatment because of injection anxiety
- More flexible daily dosing than the Wegovy pill, without the same food and water timing rules
- Clinically meaningful, though not market-leading, average weight loss based on the evidence supporting its approval
- A UK-first regulatory milestone, ahead of the rest of Europe, reflecting genuine pharmaceutical progress
These are real, worthwhile benefits. They simply need to be understood accurately, rather than inflated into claims the medicine was never shown to support.
Myths vs Facts: A Quick Reference
| Myth | Fact |
|---|---|
| Foundayo is available to buy right now | Not yet available for prescribing anywhere in the UK |
| It works completely differently to existing treatments | Same GLP-1 mechanism as Wegovy and Mounjaro, different tablet formulation |
| It produces better results than injections | Average results are lower than injectable options based on current evidence |
| There are no restrictions at all | Still requires correct daily use, gradual dosing, and medical supervision |
| It has no side effects because it’s a tablet | Similar side effect profile to other GLP-1 medicines |
| It will be on the NHS immediately | NHS access depends on a separate NICE assessment, which can take time |
| Anyone can take it once available | Still prescription-only, with eligibility assessed individually |
Why Accurate Information Matters Before Launch
When a medicine attracts this much attention before it has even launched, misinformation tends to fill the gap left by official detail. This matters for two reasons. First, patients who believe exaggerated claims may end up disappointed once treatment starts, particularly around effectiveness compared with injectable options. Second, and more seriously, hype around unavailable medicines creates an opening for unofficial sellers to claim they can supply something that cannot yet be verified as genuine or safe.
Our approach at Everest Pharmacy has always been to give patients accurate information, even when it is less exciting than a viral headline, so that whatever decision you make about your weight loss treatment is genuinely well informed. If you would like to understand how Foundayo compares to currently available options in more detail, our guide on Mounjaro vs Wegovy is a useful place to start. Alternatively, read our guide on oral weight loss alternatives if you aren’t compfortable exploring injectable options.
What To Do While You Wait For Accurate Information
If you are keen to start weight loss treatment now rather than wait for Foundayo’s exact launch date, our team can assess you for currently available, MHRA-licensed options, including Mounjaro, the Wegovy injection, and the Wegovy pill. Starting one of these treatments now does not prevent you from discussing Foundayo later, once it becomes available and your prescriber can advise whether switching makes sense for you.
To be notified as soon as Foundayo genuinely launches, rather than relying on secondhand claims, the most reliable option is to register your interest directly with us.
Frequently Asked Questions
Where do most Foundayo myths originate from?
Most inaccurate claims spread through social media summaries of news headlines, which often strip away important context and nuance from the original regulatory announcement.
Is it true that Foundayo doesn’t need to be prescribed by a doctor?
No. Foundayo will remain a prescription-only medicine once available, requiring assessment by a qualified prescriber, in the same way as existing GLP-1 treatments.
Does being “first in Europe” mean Foundayo has been tested more thoroughly than other medicines?
No. Being first in Europe reflects the timing of the UK’s regulatory decision, not a different or more rigorous testing standard than other authorised medicines.
Can I trust online sellers claiming to have Foundayo in stock already?
No. Foundayo is not yet available for prescribing in the UK, so any seller claiming otherwise cannot be verified as genuine and should be avoided.
Is it a myth that Foundayo will suit everyone who wants to avoid injections?
Yes, to an extent. While Foundayo removes the injection itself, eligibility still depends on individual health factors, and it will not be suitable for every patient who simply wants to avoid needles.
Will Foundayo’s actual UK results match the figures mentioned in early coverage?
Early figures are based on international clinical trial data. Real-world UK results may vary between individual patients, which is why they should be treated as indicative rather than guaranteed.
Is it a myth that oral GLP-1 medicines are always easier to tolerate than injections?
Yes. Tolerability depends on the individual patient and the medicine’s mechanism, not its format. Tablet and injectable GLP-1 medicines can produce similar side effects, since they work on the same pathway.
Getting The Real Picture On Foundayo
Foundayo is a genuine and welcome development in UK weight loss treatment, but it deserves to be understood accurately rather than through exaggerated online claims. Once it becomes available, we want our patients to start treatment with realistic expectations, not ones shaped by hype.
If you would like accurate advice about Foundayo or your current weight loss options, contact our team today.